A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses.
A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses.
复制标题
疫苗制造商解决与季节性和大流行性流感病毒相关的医疗需求的方法。
DOI：
10.1111/j.1750-2659.2008.00054.x
复制
发表时间：
2008-11
影响因子：
4.4
通讯作者：
Hanon, Emmanuel
中科院分区：
文献类型：
--
作者：
Baras, Benoit;Bouveret, Nancy;Devaster, Jeanne-Marie;Fries, Louis;Gillard, Paul;Saenger, Roland;Hanon, Emmanuel
摘要疫苗接种被认为是降低流感病毒引起的发病率和死亡率的最有效手段之一。为了预防季节性流感，Fluarix ™和FluLaval™分别于1987年和1992年上市。这两种疫苗一直被证明符合或超过针对H1N1、H3N2和B三种毒株的免疫原性监管标准，具有良好的安全性，并被推荐用于所有年龄段的儿童和成人接种。为了预防大流行性流感，葛兰素史克（GSK）已获得大流行前疫苗Prepandrix ™的许可。这种以AS03（一种专有的水包油乳剂佐剂系统）为佐剂的H5N1裂解病毒已被证明对漂移的H5N1毒株具有广泛的免疫力，并已被证明在动物研究中有效预防死亡和病毒脱落。GSK的流感疫苗组合可满足与季节性或大流行性流感病毒相关的特定医疗需求，这些病毒仍然是全球重要的公共卫生威胁。
Abstract Vaccination is considered to be one of the most effective tools to decrease morbidity as well as mortality caused by influenza viruses. For the prevention of seasonal influenza, Fluarix ™ and FluLaval™ have been marketed since 1987 and 1992, respectively. Both vaccines have consistently been shown to meet or exceed the regulatory criteria for immunogenicity against the three strains H1N1, H3N2 and B, have a good safety profile, and are recommended for vaccinating children and adults of all ages. For the prevention of pandemic influenza, GlaxoSmithKline (GSK) has obtained licensure of a pre‐pandemic vaccine, Prepandrix ™. This split‐virus H5N1 adjuvanted with AS03, a proprietary oil‐in‐water emulsion‐based adjuvant system, has demonstrated broad immunity against drifted H5N1 strains and has been shown to be effective in preventing mortality and viral shedding in animal studies. The influenza vaccine portfolio of GSK addresses specific medical needs related to seasonal or pandemic influenza viruses, which remain an important public health threat worldwide.
登录
查看更多内容
影响因子：
5.4
作者：
Hehme, N;Engelmann, H;Sänger, R
通讯作者：
Sänger, R
影响因子：
158.5
作者：
Abdel-Ghafar, Abdel-Nasser;Chotpitayasunondh, Tawee;Uyeki, Timothy M.
通讯作者：
Uyeki, Timothy M.
影响因子：
3.7
作者：
Hovden, AO;Cox, RJ;Haaheim, LR
通讯作者：
Haaheim, LR
影响因子：
5.5
作者：
Kunzel, W;Glathe, H;VanHoecke, C
通讯作者：
VanHoecke, C
影响因子：
168.9
作者：
Leroux-Roels, Isabel;Borkowski, Astrid;Leroux-Roels, Geert
通讯作者：
Leroux-Roels, Geert